Search

Author/Creator Chan, W. Y.

3. P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM). (23rd June 2022)

Authors:
Dimopoulos, M.; Opat, S.; D'Sa, S.; Jurczak, W.; Lee, H.-P.; Cull, G.; Owen, R. G.; Marlton, P.; Wahlin, B. E.; Garcia-Sanz, R.; McCarthy, H.; Mulligan, S.; Tedeschi, A.; Castillo, J. J.; Czyz, J.; Fernandez De Larrea Rodriguez, C.; Belada, D.; Libby, E.; Matous, J.; Motta, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1048
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P590: PRELIMINARY SAFETY AND EFFICACY OF BGB-11417, A POTENT AND SELECTIVE B-CELL LYMPHOMA 2 (BCL2) INHIBITOR, IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML). (23rd June 2022)

Authors:
Shortt, J.; Tan, S. Y.; Cannell, P.; Ng, T. F.; Fong, C. Y.; Ramanathan, S.; Rajagopal, R.; Leitch, S.; Gasiorowski, R.; Grove, C.; Lenton, D.; Tan, P.; DiNardo, C.; Ling, M. T.; Cheng, S.; Liu, Y.; Co, M.; Chan, W. Y.; Simpson, D.; Wei, A. H.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
489
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗